News | Stents Peripheral | April 27, 2018

Intact Vascular Announces $20 Million Series C Financing

Financing will fund company through pre-market approval of Tack Endovascular System

Intact Vascular Announces $20 Million Series C Financing

April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is designed to fund the company through pre-market approval (PMA) of the Tack Endovascular System for the treatment of post-angioplasty dissections above the knee.

Major participants in the Series C financing included New Enterprise Associates (NEA), H.I.G. BioVentures and Quaker Partners. The financing is structured in two stages or tranches, with the second tranche closing later in 2018.

The Tack Endovascular System is a new solution for precision dissection repair following balloon angioplasty with a first-of-its-kind implant designed to help maintain vessel integrity and enhance blood flow. This promotes healing, improves outcomes and preserves limbs. Unrepaired dissections — which are frequent following balloon angioplasty — increase the probability of acute arterial occlusion and may continue narrowing the artery, which leads to lower long-term patency rates. The Tack Endovascular System leaves a minimal amount of metal in the artery, reduces mechanical stress on the arterial wall and preserves future treatment options.

Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA III and TOBA II BTK. TOBA II is investigating the combination of the Tack device with both plain and Bard Lutonix drug-coated balloon (DCB) angioplasty in the arteries above the knee, and completed enrollment in March 2017. TOBA III is investigating the combination of the Tack system with the Medtronic In.Pact Admiral DCB in the arteries above the knee (inclusive of long lesions), and is nearing full enrollment. TOBA II BTK is investigating the combination of the Tack device with plain balloon angioplasty in the arteries below the knee and is actively enrolling patients.

For more information: www.intactvascular.com

 

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init